In conclusion, this meta-analysis demonstrates that the addition of an anti-EGFR agent to conventional RT or CRT do not improve clinical outcomes compared with CRT in patients with LA-HNSCC. Here, EGFR is linked to head and neck squamous cell carcinoma.